BioCryst Pharmaceuticals | BCRX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
Chugai Pharma JPY 162.98B 14.31B 2026-03
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
DBV Technologies USD 47.9M 2.2M 2026-03
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Gilead Sciences USD 23.52B 18.55B 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Novavax USD 126.2M 23.62M 2025-12
PTC Therapeutics USD 226.66M 19.64M 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03